SPORE in Endometrial Cancer

子宫内膜癌中的孢子

• 批准号: 7690978
• 负责人: Paul Joseph Goodfellow
• 金额: $ 70万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-18 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7690978
• 关键词: SPORE; Endometrial; Cancer

DESCRIPTION (provided by applicant): This Specialized Program of Research Excellence (SPORE) in Endometrial Cancer is submitted by Washington University in St. Louis, the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. It includes four research projects, three supportive cores, and research and career development programs. This proposal brings together basic and applied investigators to conduct innovative and diverse translational investigations aimed at preventing, diagnosing and treating endometrial cancer. The four projects in our application have been carefully designed to have significant potential to change clinical practice within five years. Project 1: FGFR2 as therapeutic target in endometrial cancer Project 2: Methylation markers for prognosis in endometrioid endometrial cancers Project 3: Identifying inherited endometrial cancer & the environmental and genetic factors contributing to somatic loss of mismatch repair Project 4: Novel effectors of ERK signaling and their potential roles in the treatment of endometrial cancer The four projects represent carefully chosen marriages between selected endometrial cancer research priorities and the strengths of Washington University and our collaborators. The critical objectives that we have chosen to focus on are to: 1) improve the treatment of patients with persistent or recurrent endometrial cancer using a molecularly targeted therapy and determine if upfront adjuvant biologic therapies hold promise for improving outcomes in the general endometrial cancer population; 2) develop prognostic markers to help guide the treatment of women with the most common form of uterine tumors, endometrioid endometrial cancer; 3) optimize detection of those women with inherited forms of endometrial cancer so they and their at-risk family members can receive risk-appropriate (intensified) cancer surveillance; and 4) elucidate the role novel effectors of ERK signaling play in uterine cancer and assess opportunities for targeting these in the treatment of endometrial cancers. Three Cores will support these projects: Administration, Tissue & Pathology, and Biostatistics. The Developmental Research Program will support a pathway for continued identification and support of diverse research that could replace or improve current projects, and a Career Development Program will recruit and support candidates committed to training in translational research in endometrial cancer.

描述（由申请人提供）：该子宫内膜癌的专业研究卓越计划（孢子）由圣路易斯的华盛顿大学，巴恩斯 - 犹太医院的现场癌症中心和华盛顿大学医学院提交。它包括四个研究项目，三个支持核心以及研究与职业发展计划。该提案汇集了基本和应用的研究人员，以进行旨在防止，诊断和治疗子宫内膜癌的创新和多样化的转化研究。我们应用程序中的四个项目经过精心设计，具有巨大的潜力，可以在五年内改变临床实践。 项目1：FGFR2作为子宫内膜癌的治疗靶标 项目2：子宫内膜化子宫内膜癌预后的甲基化标记 项目3：识别遗传的子宫内膜癌以及造成不匹配修复躯体丧失的环境和遗传因素 项目4：ERK信号传导的新型效果及其在子宫内膜癌治疗中的潜在作用 这四个项目代表了选定的子宫内膜癌研究重点与华盛顿大学的优势与我们的合作者之间精心挑选的婚姻。我们选择关注的关键目标是：1）使用分子靶向治疗改善持续或复发性子宫内膜癌患者的治疗，并确定预先辅助生物疗法是否有望改善一般子宫内膜癌群体的出现； 2）开发预后标记，以帮助指导对子宫肿瘤最常见形式的子宫内膜类子宫内膜癌的治疗； 3）优化对那些具有子宫内膜癌遗传形式的妇女的检测，以便她们及其高危家族可以接受适合风险的（加强）癌症监测； 4）阐明了ERK信号发挥在子宫癌中的新作用，并评估针对子宫内膜癌治疗的机会。 三个核心将支持这些项目：管理，组织和病理和生物统计学。该发展研究计划将支持一条持续识别和支持各种研究的途径，以取代或改善当前的项目，而职业发展计划将招募和支持致力于子宫内膜癌转化研究培训的候选人。